Rcert Solution @ Unimas
- Home
- Rcert Solution @ Unimas
Rcert Solution
Clinical Benefits of Cell Therapy by Select Fields
Regenerative Medicine
In regenerative settings, MSCs have exhibited a promising potential in osteogenesis imperfecta, Crohn’s disease, deep burns, periodontal defects, chondral/bone defects, and diabetic foot. The benefits of MSCs in clinical investigations are mostly linked, not to their multi-lineage differentiation potential, but rather to their secretome, which establishes a nutritive microenvironment, promoting autocrine and paracrine signaling that inhibits apoptosis and dictates angiogenesis, local tissue mitosis, and cross-communication with resident stem cells.
Cancer
The rationale of cancer therapy has evolved from the systemic targeting of tumors with chemotherapy/radiotherapy to a more targeted approach using novel biologic treatments, including monoclonal antibodies, oncolytic viruses, and cell therapy, such as antigen presenting cell (APC)-based anticancer vaccines and CAR-T cells. Another therapeutic approach in patients with cancer is the aforementioned regeneration of immune effectors specifically in hematological malignancies, in which case HSCT has long been the standard treatment. The year 2010 witnessed the FDA approval of PROVENGE® (sipuleucel-T), the first and only APC-based anticancer vaccine indicated for the treatment of metastatic castration-resistant prostate cancer. Later in 2017, KYMRIAH™ (tisagenlecleucel) became the first CAR-T cell therapy to receive FDA approval for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia and large B-cell lymphoma. Following tisagenlecleucel’s steps, other autologous, CD19-directed CAR-T cell therapies then entered the market with the indication of treating relapsed or refractory large B-cell lymphoma or mantle cell lymphoma. In 2021, ABECMA® (idecabtagene vicleucel) became the first B-cell maturation antigen (BCMA)-directed CAR-T cell therapy to receive FDA approval for the treatment of relapsed or refractory large B-cell lymphoma, with distinctive selectivity conferred by the highly selective expression of BCMA by malignant plasma cells.
Immunotherapy
The immune system falls roughly into two categories: the natural immunity that works against the target “cancer cells“ non-specifically and the acquired immunity that specifically works against the target. When a cancer cell appears, the natural immune cells attack and exterminate it first. However, the cancer cell can dodge their attacks and cause a “cancer.” The immunotherapy is the fourth “cancer therapy” to breach the defense structure of the cancer. Immunotherapy is treatment that uses a person’s own immune system to fight cancer. Immunotherapy can boost or change how the immune system works so it can find and attack cancer cells.
REGIONAL CELL RESEARCH & THERAPY CENTRE (RCERT)
REGIONAL CELL RESEARCH & THERAPY CENTRE (RCERT) will be based in one of the leading tertiary education institutes in Sarawak, UNIMAS to spear head the cell therapy research in the region and ultimately becomes the leader in this field in the South East Asia region, being led by renowned medical professions, assisted by the transfer technology from one of the established cell therapy research centre from China.
RCERT will have 3 main components: Cell Therapy Research Centre Cell Processing Laboratory Cell Therapy Clinical Centre
Cell Therapy Research Centre (CTR)
Cell Processing Laboratory (CPL)
Cell Therapy Clinical Centre (CTC)
WHY SARAWAK?
01
Sarawak continues to be among the top five investment destinations in Malaysia with an approved investment worth RM19.6 billion in 2020
02
Political stability
03
The Sarawak government plans to introduce an e-resident status to foreign nationals in order to facilitate the easier entry of professionals and specialists who are required for the industries in the state.
04
Sarawak’s own airline is expected to be operational by 2025, citizens from the Southeast Asian region would be able to fly to Kuching directly, without the need to transit.
05
Pan-Borneo Highway, which will later extend seamlessly to Sabah via Brunei, A major highway often becomes a catalyst for economic expansion
06
Indonesia passed a law on January 18, approving the relocation of its capital from Jakarta to East Kalimantan that will be named Nusantara, with Sarawak standing to gain from this move both directly and indirectly.
SIGNING OF MOU ON 2 MAY 2024 WITH UNIMAS WITNESSED BY DEPUTY PREMIER DATO AKMAR SIM
SIGNING OF FINAL AGREEMENT & LAUNCHING OF UNIMAS SPIN-OFF COMPANY
RCERT SOLUTIONS ON 13TH Jan 2025.
– By Prof Dr Hj Ahmad Hata bin Rasit (Vice-Chancellor of UNIMAS), Prof Dr Asri bin aid (Dean faculty of Medicine & Health Science UNIMAS), Dato Seri Chen Chow Min (Chairman of RCERT), Dr Lim Chin Seng (Medical Director RCERT)
SNEAK PEEK OF RCERT @ UNIMAS
RCERT SOLUTIONS CELL LABORATORY
SNEAK PEEK OF RCERT @ UNIMAS
RCERT SOLUTIONS AMBULATORY CARE CLINIC
Our Team
Meet Our Expert Team
Our leadership combines medical, scientific, and business expertise from Malaysia and internationally. RCERT is guided by an experienced Board of Directors, renowned physicians, and leading research scientists committed to advancing cell therapy and regenerative medicine.
Dato’ Seri Dr. Chen Chaw Min
CHAIRMAN
Dr. Lim Chin Seng
MEDICAL DIRECTOR
Professor Dr. Asri bin Said
MEDICAL DEAN UNIMAS
Mr. Loh Sheng Wei (Vin)
CHIEF EXECUTIVE OFFICER (CEO)
